Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
55.99
-0.44 (-0.78%)
At close: Jan 16, 2026, 4:00 PM EST
56.87
+0.88 (1.57%)
After-hours: Jan 16, 2026, 7:08 PM EST
Crinetics Pharmaceuticals Employees
Crinetics Pharmaceuticals had 437 employees as of December 31, 2024. The number of employees increased by 147 or 50.69% compared to the previous year.
Employees
437
Change (1Y)
147
Growth (1Y)
50.69%
Revenue / Employee
$3,513
Profits / Employee
-$968,185
Market Cap
5.74B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 437 | 147 | 50.69% |
| Dec 31, 2023 | 290 | 80 | 38.10% |
| Dec 31, 2022 | 210 | 67 | 46.85% |
| Dec 31, 2021 | 143 | 50 | 53.76% |
| Dec 31, 2020 | 93 | 25 | 36.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRNX News
- 6 days ago - Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 days ago - Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 14 days ago - Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 14 days ago - Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript - Seeking Alpha
- 14 days ago - Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia - GlobeNewsWire
- 15 days ago - Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - GlobeNewsWire
- 4 weeks ago - Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire